European Leukemia Trial Registry
Trial: RELAZA2

More Details
Scientific Title Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidin (Vidaza)
Short Title RELAZA2
Trialgroup SAL
Disease Myelodysplastic Syndrome(MDS) Intermedia II and high risk
Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status Active
Start of Recruitment 28.09.2011
Leader Platzbecker, Prof. Dr. med., Uwe
Contactperson

principal investigator
Platzbecker, Prof. Dr. med., Uwe
Tel: +49 (0)351 4582583
Fax: +49 (0)351 458-5362
Email: Uwe.Platzbecker@uniklinikum-dresden.de

Study Centre
Lehmann, Gina
Tel: +49 (0)351 458 7172
Fax: +49 (0)351 458 4367
Email: gina.lehmann@uniklinikum-dresden.de

Centre of Trial SAL-Studienzentrale, Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol
created 24.04.2012 Luise Kloos
changed 30.07.2018 Martina Wolkenfeld
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org